Company intelligence / Profile preview

Jasper Therapeutics, Inc.

Redwood City, California, United Statesir.jaspertherapeutics.com ↗

Ownership: Public · JSPR
Development stage: Phase 2

Overview

Briquilimab has demonstrated efficacy and safety in over 160 dosed subjects and healthy volunteers. Positive data has been reported from the BEACON study in CSU and the SPOTLIGHT study in CIndU, showing rapid and deep response profiles in patients with chronic urticaria. The company is advancing briquilimab into a pivotal program in CSU with a Phase 2b study expected to commence in 2025.

Therapeutic areas: PulmonologyOncologyImmunologyDermatologyHematology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

briquilimab

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $11.4M
Total revenue: $0
Enterprise value: $4.3M

Beyond the preview

Go deeper on Jasper Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jasper Therapeutics, Inc..

Explore the full profile